Previous 10 | Next 10 |
Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...
WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President ...
Eiger BioPharmaceuticals Receives FDA Acceptance of Zokinvy NDA Eiger BioPharmaceuticals, Inc. ( EIGR ) reported that the FDA has accepted its New Drug Application for accelerated review of Zokinvy (lonafarnib) for treating Progeria and Progeroid Laminopathies. The PDUFA for the drug has...
Gainers: Nano Dimension NNDM +272% . More news on: ShiftPixy, Inc., Mercurity Fintech Holding Inc., Iterum Therapeutics plc, Stocks on the move, , Read more ...
Dynavax Technologies (NASDAQ: DVAX ) +41% as COVID-19 vaccine trial could start as soon as July. More news on: Dynavax Technologies Corporation, Arbutus Biopharma Corporation, cbdMD, Inc., Stocks on the move, , Read more ...
Unless you’ve been living under a rock lately, you know how volatile the markets are right now. That has been a prime atmosphere for a “small class” of cheap equities we like to call penny stocks . Now, if you’re new to these because maybe your favorite company has b...
Gainers: ABUS +46.5% . DAC +10.1% . TNP +9.1% . BIDU +8.9% . ACB +6.4% . More news on: Arbutus Biopharma Corporation, Danaos Corporation, Tsakos Energy Navigation Limited, Stocks on the move, , Read more ...
Arbutus Biopharma (NASDAQ: ABUS ) announces positive follow-up data from a Phase 1a/1b clinical trial evaluating a single 60 mg subcutaneous injection of RNAi candidate AB-729 in patients with chronic hepatitis B virus (HBV) infection. More news on: Arbutus Biopharma Corporation, Healthc...
Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected in the second half of 2020 Conference Call and Webcast Scheduled Today at 4:3...
Gainers: CymaBay Therapeutics (NASDAQ: CBAY ) +134% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., Babcock & Wilcox Enterprises, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...